Abstract
Objective To perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate acupuncture’s clinical effect of on insulin resistance (IR) in women with polycystic ovary syndrome (PCOS).
Methods PubMed, Cochrane Library, Embase databases, and Chinese databases, including China National Knowledge Infrastructure (CNKI), Technology Journal Database (VIP), and Wanfang Database, were searched without language restrictions from inception to 20 December 2021. Only RCTs in which acupuncture had been examined as the sole or adjunctive PCOS-IR treatment were included. Additionally, only studies in Chinese databases that had been published in core journals of Peking University were included. Our primary endpoint was homeostasis model assessment of insulin resistance (HOMA-IR). The secondary outcomes were fasting blood glucose (FBG), 2-h postprandial blood glucose (2h-PBG), fasting insulin (FINS), body mass index (BMI), and adverse events. A random-effects model enabled reporting of differences between groups as mean differences, thus minimizing the effects of uncertainty associated with inter-study variability on the effects of different interventions.
Results Our analysis included seven eligible RCTs (N=728 participants). Compared with other treatments, acupuncture therapy yielded a greater mean reduction in BMI (−1.21; 95% CI, −2.41 to −0.02; P=0.05). No significant differences existed between acupuncture and other studied treatments for changes in HOMA-IR (−0.33; 95% CI, −0.87 to 0.22; P>0.05), FBG (−0.43; 95% CI, −0.88 to 0.03; P=0.07), 2h-PBG (−0.40;95% CI, −0.90 to 0.10; P>0.05), and FINS (−0.65; 95% CI, −2.18 to 0.89; P>0.05). Furthermore, compared with medication alone, a combination of acupuncture and medication yielded a mean reduction in HOMA-IR of −0.63 (95% CI, −1.12 to −0.14; P=0.01) and BMI of −1.36 (95% CI, −2.07 to −0.66; P<0.01).
Conclusion Although acupuncture is not more effective than metformin, the former could be an adjuvant strategy for improving PCOS-IR. Further large-scale, long-term RCTs with strict methodological standards are justified.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes. This work was supported by the National Natural Science Foundation of China [ grant number 81804203]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
